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A AB BS ST TR RA AC CT T
B Ba ac ck kg gr ro ou un nd d   a an nd d   O Ob bj je ec ct ti iv ve es s: : The aim of this study was
to compare in a prospective nonrandomized study, the
efficacy of 2 methods of administering methotrexate
(MTX) in the treatment of ectopic pregnancy (EP): trans-
vaginal injection under sonographic control or intramus-
cular injection (IM).
M Me et th ho od ds s: : Patients with EP who met specific inclusion
criteria for medical treatment were treated with MTX: 63
patients (group 1) were treated by IM and 47 patients
(group 2) by transvaginal local injection. In group 1, 50
mg/m2 of MTX was injected intramuscularly; in group 2,
transvaginal injection of 1 mg/kg of MTX was injected
into the ectopic sac under sonographic control. When an
additional dose of MTX was required, it was administrat-
ed IM at the dosage of 50 mg/m2 in both groups.
R Re es su ul lt ts s: : The overall success rate, defined by a posttreat-
ment normal hCG level (<10 mUI/mL) was 71.4% in
group 1 versus 91.5% in group 2 (P<0.01); for patients
with hCG levels <2000 mUI/mL, 83% and 96%, respec-
tively (not significant); for patients with hCG ≥2000
mUI/mL, 37.5% and 86.4%, respectively (P<0.01).
C Co on nc cl lu us si io on n: : In the medical treatment of EP, the efficacy
of MTX is greater when administered by local transvagi-
nal injection than by IM injection. We propose local treat-
ment every time EP can be punctured, especially when
hCG levels are ≥2000 mUI/mL.
K Ke ey y   W Wo or rd ds s: : Ectopic pregnancy, Local methotrexate, IM
methotrexate.
I IN NT TR RO OD DU UC CT TI IO ON N
Early diagnosis of ectopic pregnancy (EP) has been
made possible by a variety of factors including informa-
tion regarding its risk factors (ie, history of pelvic inflam-
matory disease, tubal surgery or ectopic pregnancy,
smoking habits, use of infertility drugs, contraception
failure), the development of radioimmunoassays, and
specific antiserum to the b-subunit of hCG that provide
sensitive and specific detection, the use of serum prog-
esterone, and high resolution sonography with vaginal
probes. When EP is discovered early, laparoscopy can
frequently be avoided, and a nonsurgical approach pro-
posed.
Since the first publication by Tanaka et al,1 many series
have reported the results of conservative medical treat-
ment with methotrexate (MTX) in EP. They have used IM
or IV injection of 1 to 4 doses,1-6 oral,7 or local injection
under laparoscopic8-10 or sonographic control.11-15 We
have previously reported MTX failure rates similar to
those reported in conservative laparoscopic surgery
when appropriate inclusion criteria are used.13 More
recently, prospective randomized studies by Hajenius et
al,16 Fernandez et al,17 and Saraj et al,18 comparing
laparoscopic salpingotomy and MTX treatment, reported
that the 2 treatments have similar success rates and sim-
ilar subsequent fertility.
However, substantial differences exist in the various sets
of results, and the success rates range from 61%15 to
93%16 for the local treatment and from 65%19,20 or 78%21
to 94%5 for the IM treatment. These discrepancies sug-
gest that selection criteria have varied from study to
study. Our continuing experience with methotrexate has
shown that the modality of administration, in particular
whether injection is IM or local transvaginal under sono-
graphic control, affects success rates. No published series
compare IM injections with the local route. We conduct-
ed this prospective, nonrandomized study in a series of
110 patients with EP, all selected according to the same
criteria.
M MA AT TE ER RI IA AL LS S   A AN ND D   M ME ET TH HO OD DS S
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and November 30, 1997. The local institutional review
board approved the nonsurgical approach for treating EP.
Criteria were an unruptured ectopic pregnancy in whom
hematosalpinx was directly visualized by pelvic ultra-
sound, a pretherapeutic score less than 13 (this score is
based on 6 criteria graded on a scale from 1 to 3: gesta-
tional age, hCG level, progesterone level, pelvic pain,
hemoperitoneum volume, and hematosalpinx diame-
ter22), and a second blood test at 48 hours showing a sta-
ble or progressing level of hCG.
During the study period, 418 EP were diagnosed overall;
286 (68.9%) underwent surgical treatment immediately
after diagnosis. Nonsurgical methods were used in 132
(31.9%) patients: 12 with expectant management when
hCG levels were decreasing at 48 hours, 10 by MTX treat-
ment IM for whom hematosalpinx was not directly visu-
alized by pelvic ultrasound, and 110 patients were includ-
ed in the study with MTX management. In this group,
MTX administration was either IM (group 1, n=63) or
injected directly into the hematosalpinx (group 2, n=47).
In group 1, the dosage of MTX IM was 50 mg/m2 as sug-
gested in the protocol of Stovall et al.4 In group 2, MTX
was injected locally without anesthesia, under sono-
graphic control, with an 18-gauge needle inserted into a
needle introducer. Penetration and aspiration of the
ectopic sac were followed by an injection of 1 mg/kg of
MTX into the hematosalpinx. The dosage of 1 mg/kg
locally was determined by a previously reported phar-
macokinetic study.23
Two groups of physicians with differing amounts of
experience with medical treatment participated in this
study: 1 group had good experience with transvaginal
puncture and usually administrated a local treatment; the
other group did not and always chose the IM route. The
same experienced physician always assumed the follow-
up of all medically treated patients. All patients were
monitored on an outpatient basis unless they lived too far
from the hospital or when the puncture was performed
after 4 pm. Patients underwent hCG assays (RIA gnost-
hCG, Behring, Marburg, Germany) on days 2, 5, and 8
after the injection and then weekly until normalization
(<10 mIU/mL). Treatment success was defined as com-
plete elimination of the tubal pregnancy (serum hCG <10
mIU/mL). All patients were aware of the possibility of
treatment failure. An additional MTX dose of 50 mg/m2
IM in both groups was required when hCG levels did not
decline according to the reference curve:13 rising hCG
levels >140% of the initial level on days 2 or 5, hCG lev-
els >100% of the initial level on day 8, no decrease at
subsequent controls. Side effects were recorded for all
patients.
To avoid an iatrogenic tubal rupture,24,25 we avoided sys-
tematic repetition of the vaginal scan and the pelvic
examination.
Characteristics and risk factors of EP were assessed for
each patient: age, parity, gravidity, history of pelvic
inflammatory disease, tubal surgery, or ectopic pregnan-
cy, smoking habits, use of infertility drugs, pregnancy
resulting from contraception failure, presence of cardiac
activity in the ectopic sac diagnosed by transvaginal
ultrasonography.
We calculated success rates after primary treatment plus
any additional dose of MTX required. Failure was
defined by the need for surgery.
Patients’ characteristics are expressed as the mean ± SD.
Indicators in the 2 groups were compared with the
Student t test and the χ2 test modified by Yates when
appropriate.
R RE ES SU UL LT TS S
Baseline demographics and characteristics are summa-
rized in T Ta ab bl le e   1 1. Slightly more patients in group 1 (IM
treatment) had a past history of pelvic inflammatory dis-
ease, and more patients in group 2 (local treatment) had
a history of tubal surgery and fertility treatments.
T Ta ab bl le e   2 2 reports the characteristics of the tubal pregnan-
cies and the success rates in both groups. In 7 cases, car-
diac activity was detected in a sac located in the cornua.
Gestational age and hematosalpinx size were the same in
both groups. Both the pretherapeutic score and proges-
terone level were slightly higher in the local treatment
group, and the pretreatment hCG level was significantly
higher (P<0.05). The overall success rate for MTX treat-
ment was 88 of 110 patients (80%). The success rate in
the IM group was 45 of 63 (71.4%). The single-dose suc-
cess rate was 41 of 63 (65.1%) patients. Twelve of 63
patients (19%) received a second MTX injection.
Treatment was successful for 4 of the 12 patients who
required a second MTX injection, but the other 8 (66.6%)
underwent surgery. Ten patients underwent surgery after
the first injection. The success rate in the local treatment
group was 43 of 47 patients (91.5%). The single-dose
success rate was 39 of 47 (83%). Five of 47 (10.6%)patients received a second MTX injection. Medical treat-
ment was successful for 4 of the 5 patients who required
a second MTX injection. Three patients underwent sur-
gery after the first injection. The difference in these suc-
cess rates for IM treatment and local treatment was sta-
tistically significant (P<0.01). Resolution time was signif-
icantly longer in the local treatment group (P<0.05).
In all, medical treatment failed in 22 cases: 18 in the IM
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treatment group and 4 in the local treatment group. The
mean initial score was 10.5±1.4 for cases with treatment
failure, and for successfully treated cases, 10.1±1.4.
Laparoscopic treatment was used for 20 of the 22 patients
for whom MTX failed. The remaining 2 patients under-
went laparotomy in another hospital, by a surgeon inex-
perienced with endoscopy. In all, 3 of 22 (13.6%)
patients had surgery elsewhere.
T Ta ab bl le e   1 1. .
Demographic and Obstetric Characteristics of 120 Patients With EP
Intramuscular Methotrexate (n=73) Local Methotrexate (n=47) P Value*
Age 31.1±5.2 (20-43) 30.6±5.7 (20-43)  NS
Parity 0.7±0.9 (0-3) 0.6±0.9 (0-3) NS
Gravidity 2.4±1.3 (1-7)  2.2±1.4 (1-6)  NS
Smoking 23 (31.5%)  11 (23.4%)  NS
Appendectomy 25 (34.2%)  18 (38.3%)  NS
Past history of EP 9 (12.3%)  8 (17%)  NS
Past history of tubal surgery 6 (8.2%) 9 (19.1%)  NS
Past history of PID 10 (13.7%) 4 (8.5%)  NS
Induction of ovulation 8 (11%)  10 (21.3%)  NS
Contraception failure 9 (12.3%)  3 (6.4%)  NS
*NS = Not significant.
T Ta ab bl le e   2 2. .
Clinical, Laboratory, and Sonographic Findings in EPs. Success Rates, Number of Doses Required, and Resolution Time
Intramuscular Methotrexate (n=73) Local Methotrexate (n=47) P Value*
Gestational age (days) 48±11.4 (35-105)  47.6±9.1 (35-70)  NS
Score 9.9±1.5 (6-12)  10.3±1.5 (7-12)  NS
Pretherapeutic hCG (mIU/mL)† 1490±2202 (116-15800) 3420±5037  (100-22600) P<0.05
Pretherapeutic Progesterone (ng/mL)‡ 6.1±5.1 (0.2-28.8) 8.6±8.7 (0.45-38.6) NS
Hematosalpinx (mm) 21±8.6 (6-43) 21.3±11 (6-52)  NS
Patients requiring additional dose
of MTX 13 (17.8%) 5 (10.6%)  NS
Resolution time§ 24±17 29.2±11.8  P<0.05
Success (return to hCG<10 mUI/mL)† 54 (74%) 43 (91.5%)  P<0.01
*NS=Not significant.
†hCG conversion factor to SI unit=1.00.
‡Progesterone level conversion factor to SI unit=3.18.
§Failure excluded.Methotrexate for the Treatment of Unruptured Tubal Pregnancy: A Prospective Nonrandomized Study, Gervaise A et al.
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The indications for secondary surgical treatment were
abdominal pain on the third day after MTX injection
(n=2); increasing or stable hCG levels (n=5); moderate
hemoperitoneum (≤250 cc) or tuboabdominal abortion
(n=11), or both of these; tubal fissure (n=3); or rupture
(n=1). Only in the latter case did an important hemoperi-
toneum occur (>1000 mL). Fifteen of 22 (68.2%) patients
underwent conservative treatment. The 7 remaining
patients underwent salpingectomy: tubal fissure or rup-
ture (n=4), unsuccessful conservative treatment (n=2),
and hydrosalpinx (n=1).
In the IM group, the mean pretreatment hCG was
1378±2609 mIU/mL for successes and 1936±1501 mIU/mL
for failures. In the local group, these values were
3404±5243 mIU/mL and 3580±2015 mIU/mL, respective-
ly. The mean pretreatment progesterone level in the IM
group was 5.9±5.4 ng/mL for successes and 6.5±4.9
ng/mL for failures. In the local treatment group, these val-
ues were 7.8±7.6 ng/mL and 16.9±15.6 ng/mL, respec-
tively. In the IM group, the mean size of hematosalpinx
before treatment was 21±8.9 mm for successes and
20.8±8 mm for failures, and in the local group 22.2±11.1
mm and 12±5 mm, respectively. No cutoff values pre-
dicting failure were found in each group for hCG or prog-
esterone levels or hematosalpinx size. When pretreat-
ment hCG levels were <2000 mIU/mL, the success rate
was 39 of 47 (83%) in the IM group and 24 of 25 (96%)
in the local treatment group. When pretreatment hCG lev-
els were ≥2000 mIU/mL, the success rate was 6 of 16 in
the IM group (37.5%) and 19 of 22 (86.4%) in the local
treatment group (P<0.01). 
Success rates according to pretreatment score are report-
ed in T Ta ab bl le e   3 3. Local injection was effective more often
than IM treatment for the same initial score. Although the
differences were not statistically significant, among
patients with an active EP and a pretherapeutic score of
12, medical treatment was successful for 5 of 10 (50%)
women in the IM group compared with 12 of 13 (92.3%)
in the local group. For a score <10, treatment was suc-
cessful for 16 of 20 (80%) women in the IM group and
all the women (12/12) in the local group.
No clinical or biological side effects were reported for
either group.
D DI IS SC CU US SS SI IO ON N
To our knowledge, this is the first study to compare the
efficacy of methotrexate IM injection to the local route
for medical management of EP. Methotrexate has been
widely used in the nonsurgical treatment of unruptured
EP and has proved its efficacy in this indication. The
great heterogenicity in the published series may be
attributed to the variety of protocols for MTX administra-
tion: systemic IM or IV injection,1-6 oral administration,7
or local injection directly into the gestational sac under
laparoscopic,8-10 or transvaginal ultrasound guid-
ance.11,13-15 Except in cases of interstitial pregnancy, we
consider that injecting MTX under laparoscopic control
tends to vitiate the main advantages of medical treat-
ment: It is minimally invasive; and in particular, it does
not require general anesthesia. A further explanation of
the discrepancies among studies lies in their different
inclusion criteria. Our patients were all selected with the
same inclusion criteria, with the pretherapeutic score
described by Fernandez et al.22 Patients with a score <13
were treated with MTX, and only if hCG levels were sta-
ble or progressing at 48 hours. Although this study was
nonrandomized, the 2 groups were comparable for
demographic data and risk factors for EP. Gestational age
T Ta ab bl le e   3 3. .
Success Rates According to Pretherapeutic Score and Cardiac Activity
Intramuscular Methotrexate Local Methotrexate P Value*
Score = 12 5/10 (50%) 12/13 (92.3%) NS
Score = 11 13/19 (68.4%) 8/9 (88.9%) NS
Score =10 14/17 (82.4%) 11/13 (84.6%) NS
Score <10 22/27 (81.5%) 12/12 (100%) NS
Cardiac activity detected in the EP 0/1 3/4 NS
*NS=Not significant.and hematosalpinx size were the same in both groups;
the pretherapeutic score and progesterone level were
slightly higher in the local treatment group, and the pre-
treatment hCG level was significantly higher in the local
treatment group (P<0.05). Despite these data, the success
rate with MTX was 45 of 63 (71.4%) patients with IM
treatment and 43 of 47 (91.5%) patients when it was
given locally (P<0.01), thereby confirming the superior
efficacy of local administration of MTX. Its higher pre-
treatment hCG levels explain the longer resolution time
in the local group.
Methotrexate is an antimetabolite that interferes with DNA
synthesis by inhibiting the action of dihydrofolate reduc-
tase. It interrupts the synthesis of the purine nucleotide
thymidylate. A previous pharmacokinetic study23 demon-
strated that when MTX was injected locally, the serum con-
centration changes determined an area under the curve
that was lower than that when MTX was given IM. These
findings may reflect decreased bioavailability of MTX cap-
tured directly by target trophoblastic cells, thereby leading
to high tissue concentrations and better efficacy.
Our results are very different from those of Lipscomb et
al6 who reported a 90.1% success rate in a series of 315
patients with EP treated with MTX IM at the dosage of 50
mg/m2. In this series, fewer than 70% of the ectopic preg-
nancies have been visualized by pelvic ultrasound. Our
results are also quite different of those of Glock et al26
who reported an 85.7% success rate in a series of 35
patients. Our results with IM treatment are closer to those
of Stika et al21 who reported a success rate of 78% in a
retrospective study of 50 patients. The results we
obtained with IM treatment may be explained by the
selection of patients for whom hCG levels were stable or
progressing at 48 hours and for whom hematosalpinx
was directly visualized. A previous study showed a 100%
specificity in the diagnosis of EP by pelvic ultrasound,17
because all patients randomized to the salpingotomy
group had hematosalpinx at laparoscopy. Our experi-
ence is probably realistic and reproducible, because it
was the fruit of work by a university hospital team with
not fewer than 10 physicians deciding whether a need
existed for secondary urgent surgery, leading sometimes
to unnecessary operations. In all the other cases, the
same experienced physician always assumed follow-up.
Our protocol, therefore, prevented any bias in subse-
quent management that might otherwise be thought to
explain the important difference between intramuscular
and local treatment results.
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Contrary to frequent statements,5,8,10 we found no cutoff
value for pretreatment hCG and progesterone levels or
hematosalpinx size. Taken one by one, none of these
results accurately predicted MTX failure. This study con-
firms that the pretherapeutic score selects patients with
EP who will be successfully treated with a local MTX
injection in more than 90% of the cases.
We found that for any given pretreatment score, results
were better in the local treatment group. When the score
was 12, only 5 of 10 (50%) attempts with IM treatment
were successful compared with 12 of 13 (92.3%) with a
local treatment. When hCG pretreatment levels were
<2000 mIU/mL, the success rate between IM and local
treatment was not significantly different: 39 of 47 (83%)
and 24 of 25 (96%), respectively. When pretreatment
hCG levels were ≥2000 mIU/mL, the success rate was 6
of 16 in the IM group (37.5%) and 19 of 22 (86.4%) in the
local group (P<0.01), confirming that local treatment
should always be considered for the treatment of an
active EP. In another study, Lipscomb et al27 reported that
among women with tubal ectopic pregnancies, a high
serum hCG concentration was the most important factor
associated with failure of treatment (but transvaginal
ultrasonography revealed an ectopic mass in only 77 per-
cent).
The results of medical treatment, when pelvic ultrasound
reveals cardiac activity in the sac, were disappointing. It
should be proposed rarely, when surgery might be partic-
ularly difficult, such as for patients with a cornual EP or
with important bowel adhesions. All patients with a score
<10 were successfully treated with local MTX, but only 16
of 20 (80%) IM treatments were successful. We conclude
that justification exists for the puncture of all EPs suitable
for medical treatment, even for those of low activity.
As with all new techniques, physicians need training to
perform transvaginal MTX injection under sonographic
guidance; with it, they improve rapidly. In this case, no
specific tools are needed, and the procedure is as simple
as puncturing an ovarian cyst or a follicle. Though it
takes more time and is substantially more difficult than a
simple intramuscular injection, our results suggest that it
is worthwhile to puncture ectopic pregnancies with a
score <13 every time the hematosalpinx has been visual-
ized by pelvic ultrasound and that procedure seems safe.
If hematosalpinx has not been detected or is not acces-
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choice when a nonsurgical approach is possible.
Obviously, the lack of randomization reduces the value
of the comparison. Results should be confirmed in a
prospective, randomized trial.
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